Myriad Genetics Appoints Ben Wheeler Chief Financial Officer
Myriad Genetics (NASDAQ: MYGN) has announced the promotion of Ben Wheeler to Chief Financial Officer, effective August 16, 2025. Wheeler, a 13-year company veteran, previously served as chief financial officer of operations and has held various leadership roles since joining in 2011.
The appointment follows Scott Leffler's transition to a consulting role through September 2, 2025. CEO Sam Raha expressed confidence in Wheeler's ability to execute the company's profitable growth strategy. The company has also reaffirmed its full-year 2025 financial guidance as previously announced on August 5, 2025.
Myriad Genetics (NASDAQ: MYGN) ha annunciato la promozione di Ben Wheeler a Chief Financial Officer, con decorrenza dal 16 agosto 2025. Wheeler, che vanta 13 anni in azienda, ricopriva in precedenza il ruolo di chief financial officer delle operazioni e ha svolto diverse posizioni di leadership dal suo ingresso nel 2011.
La nomina segue il passaggio di Scott Leffler a un incarico di consulente fino al 2 settembre 2025. L’amministratore delegato Sam Raha ha espresso fiducia nella capacità di Wheeler di attuare la strategia aziendale di crescita redditizia. La società ha inoltre confermato le previsioni finanziarie per l’intero 2025 come precedentemente comunicate il 5 agosto 2025.
Myriad Genetics (NASDAQ: MYGN) ha anunciado el ascenso de Ben Wheeler a Chief Financial Officer, con efecto a partir del 16 de agosto de 2025. Wheeler, veterano de la compañía con 13 años de experiencia, desempeñaba anteriormente el puesto de chief financial officer de operaciones y ha ocupado diversos cargos directivos desde su incorporación en 2011.
El nombramiento se produce tras la transición de Scott Leffler a un puesto de consultor hasta el 2 de septiembre de 2025. El consejero delegado Sam Raha manifestó su confianza en la capacidad de Wheeler para ejecutar la estrategia de crecimiento rentable de la compañía. La empresa también ha reafirmado su guía financiera para todo el año 2025, tal como se anunció el 5 de agosto de 2025.
Myriad Genetics (NASDAQ: MYGN)는 Ben Wheeler를 최고재무책임자로 승진시키며 그 효력은 2025년 8월 16일부터라고 발표했습니다. 회사에 13년 몸담아 온 Wheeler는 이전에 운영 최고재무책임자 역할을 맡았고 2011년 입사 이래 여러 리더십 직책을 수행해 왔습니다.
이번 임명은 Scott Leffler가 2025년 9월 2일까지 컨설턴트로 전환한 데 따른 것입니다. CEO Sam Raha는 Wheeler가 회사의 수익성 있는 성장 전략을 실행할 수 있을 것이라는 신뢰를 표명했습니다. 회사는 또한 2025년 전체 재무 가이던스를 2025년 8월 5일 발표한 바와 같이 재확인했습니다.
Myriad Genetics (NASDAQ: MYGN) a annoncé la promotion de Ben Wheeler au poste de Chief Financial Officer, effective au 16 août 2025. Wheeler, qui compte 13 années au sein de l’entreprise, occupait auparavant la fonction de chief financial officer des opérations et a tenu plusieurs postes de direction depuis son arrivée en 2011.
Cette nomination intervient après la transition de Scott Leffler vers un rôle de consultant jusqu’au 2 septembre 2025. Le PDG Sam Raha a exprimé sa confiance dans la capacité de Wheeler à exécuter la stratégie de croissance rentable de l’entreprise. La société a également réaffirmé ses orientations financières pour l’ensemble de l’année 2025, telles qu’annoncées le 5 août 2025.
Myriad Genetics (NASDAQ: MYGN) hat die Beförderung von Ben Wheeler zum Chief Financial Officer bekanntgegeben, wirksam zum 16. August 2025. Wheeler, der seit 13 Jahren im Unternehmen ist, war zuvor Chief Financial Officer für den operativen Bereich und hatte seit seinem Eintritt im Jahr 2011 verschiedene Führungspositionen inne.
Die Ernennung erfolgt nach dem Wechsel von Scott Leffler in eine Beratungsrolle bis zum 2. September 2025. CEO Sam Raha äußerte Vertrauen in Wheelers Fähigkeit, die profitable Wachstumsstrategie des Unternehmens umzusetzen. Das Unternehmen hat zudem seine finanzielle Prognose für das Gesamtjahr 2025, wie bereits am 5. August 2025 bekanntgegeben, bestätigt.
- Internal promotion demonstrates strong succession planning and stability
- New CFO brings 13 years of company-specific experience
- Reaffirmation of 2025 financial guidance indicates business stability during transition
- Departure of previous CFO after only 20 months in the role
SALT LAKE CITY, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Ben Wheeler has been promoted to Chief Financial Officer, effective August 16, 2025.
Ben has been with Myriad for more than 13 years, joining the Company in December 2011 as assistant controller and advancing through leadership roles including vice president, corporate controller; senior vice president, accounting; and since 2022, chief financial officer, operations.
Scott Leffler, who has served as Chief Financial Officer since January 2024, will transition to a consulting role serving the CEO and the Board of Directors through September 2, 2025.
“We want to thank Scott for his contributions to Myriad,” said Sam Raha, President and CEO of Myriad Genetics. “We are happy to have Ben as our next CFO. His extensive knowledge of our business, strong financial expertise, and proven leadership will be instrumental in enabling the execution of our profitable growth strategy going forward.”
“I’m excited for this opportunity to lead the finance team and play a pivotal role in advancing Myriad’s mission and long-term growth strategy,” said Mr. Wheeler. “I look forward to partnering with Sam and the rest of the executive team to positively impact an increasing number of patient lives and to generate lasting value for our shareholders.”
The company is reaffirming its financial guidance for the full-year 2025, as announced during its second quarter 2025 earnings call on August 5, 2025.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including that the company is reaffirming its financial guidance for the full-year 2025, as announced during its second quarter 2025 earnings call, and that Mr. Wheeler’s extensive knowledge of the company’s business, strong financial expertise, and proven leadership will be instrumental in enabling the execution of the company’s profitable growth strategy going forward. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 28, 2025, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Kate Schraml
(224) 875-4493
PR@myriad.com
FAQ
Who is the new CFO of Myriad Genetics (MYGN)?
Why is Scott Leffler leaving as Myriad Genetics CFO?
What is Ben Wheeler's experience at Myriad Genetics (MYGN)?
Will Myriad Genetics (MYGN) change its 2025 financial guidance due to the CFO transition?
When does Ben Wheeler start as Myriad Genetics CFO?
